Loading
NYSEHealthcareMedical - Devices
Latest quote
$165.69
+$4.40 · +2.73%
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Previous close
$165.69
+$4.40 · +2.73%
After-hours
$165.69
$0.00 · 0.00%
Oct 9, 4:20 PM ET
Regular session · ET · Market data may be delayed.
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Day range
Current $165.69
52-week range
Current $165.69
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
58
Fair Value
Sentiment
60
Mixed
Risk
33
Moderate Risk
Momentum
72
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Day range
Current $165.69
52-week range
Current $165.69
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 507.44M USD | 383.48M USD | 314.71M USD | 282.86M USD | 294.01M USD |
| Cost of goods sold | 114.23M USD | 94.03M USD | 75.58M USD | 68.98M USD | 66.63M USD |
| Gross profit | 393.22M USD | 289.45M USD | 239.14M USD | 213.88M USD | 227.38M USD |
| Research and development | 150.61M USD | 136.43M USD | 138.77M USD | 123.27M USD | 101M USD |
| Selling, general, and administrative | 329.34M USD | 262.85M USD | 224.07M USD | 192.93M USD | 179.26M USD |
| Operating expenses | 479.95M USD | 411.82M USD | 367.84M USD | 296.2M USD | 260.26M USD |
| Interest income | 10.71M USD | 11.11M USD | 9.16M USD | 2.38M USD | 1.29M USD |
| Interest expense | 4.64M USD | 10.04M USD | 13.63M USD | 13.72M USD | 13.37M USD |
| Depreciation and amortization | 42.35M USD | 39.92M USD | 37.98M USD | 35.95M USD | 34.42M USD |
| Operating income | −86.73M USD | −122.37M USD | −128.7M USD | −82.31M USD | −32.87M USD |
| Net income | −187.69M USD | −146.37M USD | −134.66M USD | −99.2M USD | −49.59M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$192.89
16.42% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI318.41M0.01%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM245.32M0.31%78.27B USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB230.51M0.12%185.3B USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK132.32M0.29%44.7B USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF122.54M0.13%95.4B USD0.05%$235+0.80%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM87.2M0.55%15.84B USD0.03%$53.45+0.17%
iShares Russell 2000 Growth ETFIWO85.92M0.62%13.97B USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO59.53M0.32%18B USD0.06%$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
